Literature DB >> 21217398

Predictive ability of Charlson comorbidity index on outcomes from lung cancer.

Apar Kishor Ganti1, Emily Siedlik, Alissa S Marr, Fausto R Loberiza, Anne Kessinger.   

Abstract

BACKGROUND: The effect of age and/or comorbidities on management decisions in lung cancer patients has been debated. The Charlson Comorbidity Index (CCI) was developed to help predict mortality from chronic medical conditions. This study was undertaken to evaluate whether CCI is correlated with survival in lung cancer. PATIENTS AND METHODS: A retrospective chart review of 617 lung cancer patients diagnosed between 1994 and 2007 was conducted. CCI was calculated for each patient with and without the inclusion of age. Multivariate Cox proportional hazard regression analysis was used to evaluate the relationship between CCI and survival while adjusting for other prognostic factors.
RESULTS: Six patients were excluded from the final analysis due to missing outcome or comorbidity data. The median age at diagnosis was 64 years (range, 16-89 y). Five hundred fourteen patients (84%) had nonsmall cell lung cancer and 97 patients (16%) had small cell lung cancer. Using multivariate analysis, no correlation was found between CCI and risk of death whether or not age was included in the index score.
CONCLUSIONS: CCI did not provide predictive validity for survival of lung cancer patients. Development of accurate and predictive prognostic models to help estimate a patient's prognosis is needed.

Entities:  

Mesh:

Year:  2011        PMID: 21217398     DOI: 10.1097/COC.0b013e3181fe445b

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  13 in total

1.  Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer.

Authors:  Daniel H Ahn; Nishi Mehta; Jeffrey T Yorio; Yang Xie; Jingsheng Yan; David E Gerber
Journal:  Clin Lung Cancer       Date:  2013-07-22       Impact factor: 4.785

2.  Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer.

Authors:  Mani Keshtgarpour; Wei Seong Tan; Jack Zwanziger; Saria Awadalla; Fredrick G Langi; Arkadiusz Z Dudek
Journal:  Anticancer Res       Date:  2016-04       Impact factor: 2.480

3.  Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period.

Authors:  Achuta Kumar Guddati; Parijat Saurav Joy; Gagan Kumar
Journal:  J Cancer Res Clin Oncol       Date:  2016-02       Impact factor: 4.553

4.  Impact of comorbidity on lung cancer mortality - a report from the Liverpool Lung Project.

Authors:  Michael W Marcus; Ying Chen; Stephen W Duffy; John K Field
Journal:  Oncol Lett       Date:  2015-01-28       Impact factor: 2.967

5.  Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.

Authors:  Ching-Heng Lin; Kuo-Hsuan Hsu; Shih-Ni Chang; Hsi-Kai Tsou; Jason Sheehan; Meei-Ling Sheu; Hung-Chuan Pan
Journal:  Radiat Oncol       Date:  2015-06-06       Impact factor: 3.481

6.  Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer.

Authors:  Lei Zhao; Lai-Han Leung; Jing Wang; Huihui Li; Juanjuan Che; Lian Liu; Xiaojun Yao; Bangwei Cao
Journal:  BMC Pulm Med       Date:  2017-08-15       Impact factor: 3.317

7.  Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer.

Authors:  Oliver Edwin Holmes; Robert MacRae; Graham Cook; Peter Cross; Vimoj Nair; Horia Marginean; Jason R Pantarotto
Journal:  Clin Transl Radiat Oncol       Date:  2017-08-02

8.  Are comorbidities associated with long-term survival of lung cancer? A population-based cohort study from French cancer registries.

Authors:  A Seigneurin; P Delafosse; B Trétarre; A S Woronoff; M Velten; P Grosclaude; A V Guizard; B Lapôtre-Ledoux; S Bara; F Molinié; M Colonna
Journal:  BMC Cancer       Date:  2018-11-12       Impact factor: 4.430

9.  Investigation on Advanced Non-Small-Cell Lung Cancer among Elderly Patients Treated with Chinese Herbal Medicine versus Chemotherapy: A Pooled Analysis of Individual Data.

Authors:  Lingling Sun; Wan Sze Yim; Paul Fahey; Shutang Wang; Xiaoshu Zhu; Jing Qiao; Hezheng Lai; Lizhu Lin
Journal:  Evid Based Complement Alternat Med       Date:  2019-01-02       Impact factor: 2.629

Review 10.  First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly.

Authors:  Tania Losanno; Cesare Gridelli
Journal:  Curr Oncol Rep       Date:  2021-08-03       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.